$-0.03
(Market cap
$371 Mln
Recently Viewed
Clear AllMarket cap
$371 Mln
Revenue (TTM)
$15 Mln
P/E Ratio
--
P/B Ratio
8.8
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-1.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-8.8
Debt to Equity
0.1
Book Value
$0.2
EPS
$-0.3
Face value
--
Shares outstanding
249,087,529
CFO
$-289.89 Mln
EBITDA
$-518.35 Mln
Net Profit
$-234.71 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lineage Cell Therapeutics (LCTX)
| -12.3 | -17.2 | -14.3 | 253.4 | 2.3 | -10.7 | -7.0 |
|
BSE Sensex
| -8.4 | 0.0 | -7.2 | 5.0 | 9.0 | 9.4 | 12.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Lineage Cell Therapeutics (LCTX)
| 232.3 | -53.6 | -6.8 | -52.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lineage Cell Therapeutics (LCTX)
|
1.5 | 371.1 | 14.6 | -63.5 | -328.0 | -103.4 | -- | 8.8 |
| 65.1 | 9,121.7 | 1,091.0 | 202.3 | 31.6 | 31.3 | 40.7 | 16.0 | |
| 239.3 | 14,690.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 65.0 | 8,006.8 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.3 | 11,869.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.9 | 5.3 | |
| 78.6 | 10,310.0 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 519.6 | 11,919.8 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.8 | |
| 493.5 | 14,094.3 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.3 | 30.7 | |
| 102.7 | 8,077.1 | 0.0 | -425.4 | -- | -36.7 | -- | 6.5 | |
| 316.1 | 8,804.8 | 0.0 | -303.3 | -- | -45.8 | -- | 10.0 |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment... epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. Read more
CEO, President & Director
Mr. Brian M. Culley M.A., M.B.A.
CEO, President & Director
Mr. Brian M. Culley M.A., M.B.A.
Headquarters
Carlsbad, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Lineage Cell Therapeutics Inc (LCTX) is $1.47 (NYSE) as of 10-Apr-2026 13:44 EDT. Lineage Cell Therapeutics Inc (LCTX) has given a return of 2.26% in the last 3 years.
Since, TTM earnings of Lineage Cell Therapeutics Inc (LCTX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-6.05
|
8.63
|
|
2024
|
-5.41
|
1.28
|
|
2023
|
-8.76
|
2.97
|
|
2022
|
-7.57
|
2.71
|
|
2021
|
-9.55
|
4.45
|
The 52-week high and low of Lineage Cell Therapeutics Inc (LCTX) are Rs 2.09 and Rs 0.38 as of 12-Apr-2026.
Lineage Cell Therapeutics Inc (LCTX) has a market capitalisation of $ 371 Mln as on 10-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Lineage Cell Therapeutics Inc (LCTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.